CLINICAL results have demonstrated the importance of oestrogens in the growth regulation of some breast cancers (Jensen et al., 1973) . Other hormones, such as )rolactin, may be involved in the growth of mammary cancer. Prolactin is already known to be essential for the growth of many rat mammary tumours (for review, see Boyns and Griffiths, 1972) .
This communication demonstrates, directly and indirectly, that prolactin supports growth of transplantable GR mouse mammary tumours that grow in spayed mice treated with progesterone plus oestrone and do not grow in untreated spayed mice.
MATERIALS AND METHODS
Chen icals. Progesterone and oestrone were generously provided by Leo Pharmaceuticals, Ballerup, Denmark. Bromocriptine (2-Br-a-ergokryptine-methanesulphonate) -was donated by Sandoz, Basel, Switzerland.
Ovine prolactin (20-25 iu/mg) wNas supplied by Ferring AB, Malmo, Sweden. The remaining, chemicals w-ere of analytical grade.
Tumour mlodel. Mammary carcinomas were induced in spayed mice of the GRS/AFib strain according to the method of van Nie (personal communication, 1970) . Ten-to-12-week-old female mice were spayed and immediately treated with progesterone plus oestrone (p + o). Progesterone pellets prepared from a paste of progesterone and olive oil were injected s.c. once a week at, a dose of 5-10 mg. Oestrone was dissolved in ethanol and added to the drinking water (redistilled water) at a concentration of 0-5 ,ug/ml. S.c. transplantation of induced tumours was carried out using either minced tumour tissue or tumour cells isolated enzyTmat,ically according to the method of Wiepjes and Prop (1970) Experiments wvith bromocriptine.-Six mice were spayed for each of 5 experiments with HD tumours and immediately treated in the following manner: 2 were treated with p + o as above, 2 with p + o + bromocriptine (0-2 mg s.c. per day), and 2 untreated. One week later, tumour tissue from a single, primary tumour was transplanted to each of the 6 animals. HI tumours were transplanted to 4 animals only, 2 receiving treatment with bromocriptine and 2 untreated.
The animals were observed twice weekly. When the largest tumour reached approximately 1 cm3 in size, all animals within the single experiment were killed, and the tumours were removed and weighed.
Statistics
Statistical evaluation wAas performed writh the non-parametric Wilcoxon rank-sum test.
RESULTS
The effects of prolactin, p + o + prolactin, and p + o, on regrowth of regressing HD mammary tumours, were studied in 6 experiments. The results are shown in Fig. 1 . In all 6 experiments, treatment with prolactin alone supported tumour growth for several days, whereas tumours continued to regress in all control mice injected only with buffer. In each of the experiments, the final volume of the tumours in the prolactin-treated group was significantly higher (P < 0 01) than that of the tumours in the control groups. Futhermore, prolactin significantly stimulated (P < 0 02) (p + o)-supported tumour growth in 1 (Experiment D) of 3 experiments. Administration of prolactin had no significant effect (P > 01d0) on the growth of HI tumours (Fig. 2) .
The growth of HD tumours transplanted to spayed mice receiving bromocriptine + p + o was studied in 5 experiments. In all of these, mean tumour volume was lower in animals treated with bromocriptine + p + o than in controls treated with p + o alone (Fig.  3) . This difference is statistically significant (P < 0.05) as tested by the P. BRIAND, S. M. THORPE, AND J. L. DAEHNFELDT tumour growth in treated mice did not differ from that in the untreated, control mice (Fig. 4) Fig.) .
DISCUSSION
The importance of prolactin in mammary tumour induction has previously been established in rats and mice by demonstrating a significantly higher tumour incidence under various conditions leading to increased serum prolactin levels (Boot, 1970; Meites, 1972) , and by demonstrating a significantly lower tumour incidence during administration of bromocriptine, an inhibitor of prolactin secretion (Stahelin, BurckhardtVischer and Fliickiger, 1972;  Yanai and Nagasawa, 1972; Welsch and Gribler, 1973; Chan and Cohen, 1974 Prolactin has also been shown to stimulate the growth of pre-existing mammary tumours in DMBA-treated rats (Pearson et al., 1969; Welsch, Clemens and Meites, 1969; Nagasawa and Yanai, 1970; Leung and Sasaki, 1975) . Furthermore, when prolactin secretion is diminished in carcinogen-treated rats (by administration of bromocriptine), mammary tumour growth has been found to be inhibited (Heuson, Waelbroeck-Van Gaver and Legros 1970; Nagasawa and Meites, 1970 ).
In the mouse, the role of prolactin in mammary tumour growth has been less thoroughly investigated. Most mouse mammary tumours are HI (Miihlbock, 1955) . However, in a few inbred strains, such as the BR strains (Foulds, 1949) , the DD strain (Heston, (Lee, 1970) . Since prolactin levels are high in early pregnancy in the mouse (Murr, Bradford and (Xeschwind, 1974) , it is feasible that prolactin is involved in the growth of these pregnancy-dependent tumours.
The finding in BR6 mice that 4/7 tumours induced by grafting pituitary glands under the kidney capsule ceased to grow after removal of the graft-bearing kidney, offers further indication for the involvement of prolactin in the growth of mouse mammary tumours.
In the GR strain of mice, mammary tumours can be induced by forced breeding (van Nie and Dux, 1971) or by treatment of spayed mice with p + o (van Nie, personal communication,) . Most of the mammary tumours induced by p + o treatment are dependent upon the continued administration of p + o for growth (Briand and Daehnfeldt, 1973; Sluyser and van Nie, 1974) . Since longsustained administration of oestrogens is known to lead to enlargement of the pituitary gland and increased production of prolactin in mice (Kim, Furth and Yannopoulos, 1963; Boot, Kwa and Rdpcke, 1973; Chan and Cohen, 1974) prolactin might be involved in the stimulation of growth of these (p + o)-dependent GTR mouse mammary tumours.
We have found that administration of prolactin alone leads to regrowth of regressing GR mouse mammary tumours. The growth rate of tumours in mice treated with prolactin was not, however, as great as that in the (p + o)-treated mice. This may have been due to use of heterologous prolactin or maintenance of suboptimal levels of prolactin throughout part of the experiment. Provided that the half-life of prolactin in mice is of the same order as that found in rats Fig. 3 ). In the fifth experiment one of the control mice for unknown reasons did not develop any tumour. The other one produced a tumour which weighed more than the tumours in the 2 mice which received bromocriptine.
When the results of all 5 experiments were evaluated by the Wilcoxon rank-sum test the inhibitory effect of bromocriptine was found to be statistically significant. An unspecific, toxic effect of bromocriptine on tumour growth is unlikely but cannot be excluded, since animals bearing HD tumours were treated with bromocriptine for a longer period of time than animals bearing HI tumours.
A difference in time of treatment was unavoidable, since the same amount of tumour tissue was transplanted to each mouse, and the treatment period was not extended beyond the exponential growth phase of the tumour.
In conclusion, evidence has been presented for the involvement of prolactin in the growth of transplanted, hormonedependent GR mouse mammary tumours. 
